A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis
Information source: Greiner, Jack V., OD DO PhD
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Conjunctivitis, Allergic
Intervention: Olopatadine (Drug); Fluticasone (Drug); Saline (Drug); Artificial tears (Drug)
Phase: Phase 4
Sponsored by: Greiner, Jack V., OD DO PhD
Official(s) and/or principal investigator(s):
Jack V Greiner, OD, DO, PhD, Principal Investigator, Affiliation: Ophthalmic Research Associates
To compare the clinical efficacy of olopatadine and fluticasone in a 3-week single center,
double-masked, randomized, placebo controlled parallel treatment conjunctival allergen
challenge (CAC) study in patients with allergic conjunctivitis
Official title: A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis
Study design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Primary outcome: Ocular itching
Secondary outcome: Ocular redness
Study will evaluate the efficacy of nasal anti-allergic therapy compared to ocular
anti-allergic therapy in the prevention of ocular allergic symptoms.
Minimum age: 18 Years.
Maximum age: N/A.
- At least 18 years of age & either sex, any race
- Willing and able to follow all instructions and attend all study visits
- Positive history of ocular allergies
- Reproducible positive ocular allergic reaction induced by conjunctival allergen
- Have planned surgery during trial period
- Female currently pregnant, planning a pregnancy, or lactating
- Use of disallowed medications
Locations and Contacts
Ophthalmic Research Associates, Inc, North Andover, Massachusetts 01845, United States
Starting date: February 2008
Ending date: March 2008
Last updated: April 2, 2008